SLC5A2 and chronic kidney disease: Our study suggests that SGLT2 inhibitors prescribed in CKD and T2DM patients are associated with increased uric acid fractional excretion (FE), which remains directly proportional to glucose FE over time, irrespective of glomerular filtration loss.